{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:04Z","timestamp":1790938084540,"version":"4.1.0"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2022-0516_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Timely diagnosis of Alzheimer\u2019s disease (AD) is critical for appropriate treatment\/patient management. Cerebrospinal fluid (CSF) biomarker analysis is often used to aid diagnosis. We assessed analytical performance of second-generation (Gen II) Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      CSF immunoassays (Roche Diagnostics International Ltd), and adjusted existing cut-offs, to evaluate their potential utility in clinical routine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2022-0516_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analytical performance was assessed using CSF samples measured with Elecsys CSF Gen II immunoassays on cobas e analyzers. A\u03b242 Gen I\/Gen II immunoassay method comparisons were performed (Passing-Bablok regression). Cut-off values were adjusted using estimated bias in biomarker levels between BioFINDER protocol aliquots\/Gen I immunoassays and Gen II protocol aliquots\/immunoassays. Distribution of Gen II immunoassay values was evaluated in AD, mild cognitive impairment (MCI), and cognitively normal cohorts; percentage observations outside the measuring range were derived.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2022-0516_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Gen II immunoassays demonstrated good analytical performance, including repeatability, intermediate precision, lot-to-lot agreement (Pearson\u2019s r:\u00a0\u22650.999), and platform agreement (Pearson\u2019s r:\u00a0\u22650.995). A\u03b242 Gen I\/Gen II immunoassay measurements were strongly correlated (Pearson\u2019s r: 0.985\u20130.999). A\u03b242 Gen II immunoassay cut-offs were adjusted to 1,030 and 800\u00a0ng\/L, and pTau181\/A\u03b242 ratio cut-offs to 0.023 and 0.029, for Gen II and I protocols, respectively. No observations were below the lower limit of the measuring range; above the upper limit, there were none from the AD cohort, and 2.6 and 6.8% from the MCI and cognitively normal cohorts, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2022-0516_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that the Gen II immunoassays have potential utility in clinical routine to aid diagnosis of AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2022-0516","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T14:36:19Z","timestamp":1666708579000},"page":"234-244","source":"Crossref","is-referenced-by-count":26,"title":["Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer\u2019s disease"],"prefix":"10.1515","volume":"61","author":[{"given":"Kaj","family":"Blennow","sequence":"first","affiliation":[{"name":"Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , M\u00f6lndal , Sweden"},{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology , the Sahlgrenska Academy at the University of Gothenburg , M\u00f6lndal , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Malm\u00f6, Clinical Memory Research Unit , Lund University , Malm\u00f6 , Sweden"},{"name":"Memory Clinic , Sk\u00e5ne University Hospital , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , M\u00f6lndal , Sweden"},{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology , the Sahlgrenska Academy at the University of Gothenburg , M\u00f6lndal , Sweden"},{"name":"Department of Neurodegenerative Disease , UCL Institute of Neurology , London , UK"},{"name":"UK Dementia Research Institute at UCL , London , UK"},{"name":"Hong Kong Center for Neurodegenerative Disease , Shatin, N.T. , Hong Kong , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Borlinghaus","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Corradini","sequence":"additional","affiliation":[{"name":"Roche Diagnostics International Ltd , Rotkreuz , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Manuilova","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"M\u00fcller-H\u00fcbner","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances-Catherine","family":"Quevenco","sequence":"additional","affiliation":[{"name":"Roche Diagnostics International Ltd , Rotkreuz , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Rutz","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Malm\u00f6, Clinical Memory Research Unit , Lund University , Malm\u00f6 , Sweden"},{"name":"Memory Clinic , Sk\u00e5ne University Hospital , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"2023032404532957047_j_cclm-2022-0516_ref_001","doi-asserted-by":"crossref","unstructured":"Dubois, B, Hampel, H, Feldman, HH, Scheltens, P, Aisen, P, Andrieu, S, et al.. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimer\u2019s Dementia 2016;12:292\u2013323. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.002.","DOI":"10.1016\/j.jalz.2016.02.002"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_002","doi-asserted-by":"crossref","unstructured":"Lam, J, Hl\u00e1vka, J, Mattke, S. The potential emergence of disease-modifying treatments for Alzheimer disease: the role of primary care in managing the patient journey. J Am Board Fam Med 2019;32:931\u201340. https:\/\/doi.org\/10.3122\/jabfm.2019.06.180328.","DOI":"10.3122\/jabfm.2019.06.180328"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_003","doi-asserted-by":"crossref","unstructured":"Cummings, J, Aisen, P, Apostolova, LG, Atri, A, Salloway, S, Weiner, M. Aducanumab: appropriate use recommendations. J Prev Alzheimer\u2019s Dis 2021;8:398\u2013410. https:\/\/doi.org\/10.14283\/jpad.2021.41.","DOI":"10.14283\/jpad.2022.34"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_004","doi-asserted-by":"crossref","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat Med 2021;27:954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","DOI":"10.1038\/s41591-021-01382-x"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_005","doi-asserted-by":"crossref","unstructured":"Scheltens, P, De Strooper, B, Kivipelto, M, Holstege, H, Ch\u00e9telat, G, Teunissen, CE, et al.. Alzheimer\u2019s disease. Lancet 2021;397:1577\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4.","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_006","doi-asserted-by":"crossref","unstructured":"Hansson, O, Lehmann, S, Otto, M, Zetterberg, H, Lewczuk, P. Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 2019;11:34. https:\/\/doi.org\/10.1186\/s13195-019-0485-0.","DOI":"10.1186\/s13195-019-0485-0"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_007","doi-asserted-by":"crossref","unstructured":"Hansson, O, Seibyl, J, Stomrud, E, Zetterberg, H, Trojanowski, JQ, Bittner, T, et al.. Swedish BioFINDER study group; Alzheimer\u2019s disease neuroimaging initiative. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer\u2019s Dement 2018;14:1470\u201381. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010.","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_008","doi-asserted-by":"crossref","unstructured":"Schindler, SE, Gray, JD, Gordon, BA, Xiong, C, Batrla-Utermann, R, Quan, M, et al.. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer\u2019s Dementia 2018;14:1460\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.013.","DOI":"10.1016\/j.jalz.2018.01.013"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_009","doi-asserted-by":"crossref","unstructured":"Willemse, EAJ, Tijms, BM, van Berckel, BNM, Le Bastard, N, van der Flier, WM, Scheltens, P, et al.. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer\u2019s Dement (Amst) 2021;13:e12182. https:\/\/doi.org\/10.1002\/dad2.12182.","DOI":"10.1002\/dad2.12182"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_010","doi-asserted-by":"crossref","unstructured":"Blennow, K, Shaw, LM, Stomrud, E, Mattsson, N, Toledo, JB, Buck, K, et al.. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1\u201342), pTau and tTau CSF immunoassays. Sci Rep 2019;9:19024. https:\/\/doi.org\/10.1038\/s41598-019-54204-z.","DOI":"10.1038\/s41598-019-54204-z"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_011","doi-asserted-by":"crossref","unstructured":"Doecke, JD, Ward, L, Burnham, SC, Villemagne, VL, Li, Q-X, Collins, S, et al.. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimer\u2019s Res Ther 2020;12:36. https:\/\/doi.org\/10.1186\/s13195-020-00595-5.","DOI":"10.1186\/s13195-020-00595-5"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_012","doi-asserted-by":"crossref","unstructured":"Hansson, O, Mikulskis, A, Fagan, AM, Teunissen, C, Zetterberg, H, Vanderstichele, H, et al.. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: a review. Alzheimer\u2019s Dement 2018;14:1313\u201333. https:\/\/doi.org\/10.1016\/j.jalz.2018.05.008.","DOI":"10.1016\/j.jalz.2018.05.008"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_013","doi-asserted-by":"crossref","unstructured":"Hansson, O, Rutz, S, Zetterberg, H, Bauer, E, H\u00e4hl, T, Manuilova, E. Pre-analytical protocol for measuring Alzheimer\u2019s disease biomarkers in fresh CSF. Alzheimer\u2019s Dement (Amst) 2020;12:e12137. https:\/\/doi.org\/10.1002\/dad2.12137.","DOI":"10.1002\/dad2.12137"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_014","doi-asserted-by":"crossref","unstructured":"Hansson, O, Batrla, R, Brix, B, Carillo, MC, Corradini, V, Edelmayer, RM, et al.. The Alzheimer\u2019s Association International guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau. Alzheimer\u2019s Dement 2021;17:1575\u201382. https:\/\/doi.org\/10.1002\/alz.12316.","DOI":"10.1002\/alz.12316"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_015","doi-asserted-by":"crossref","unstructured":"Boulo, S, Kuhlmann, J, Andreasson, U, Brix, B, Venkataraman, I, Herbst, V. First amyloid \u03b21-42 certified reference material for re-calibrating commercial immunoassays. Alzheimer\u2019s Dement 2020;16:1493\u2013503. https:\/\/doi.org\/10.1002\/alz.12145.","DOI":"10.1002\/alz.12145"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_016","doi-asserted-by":"crossref","unstructured":"Janelidze, S, Stomrud, E, Brix, B, Hansson, O. Towards a unified protocol for handling of CSF before \u03b2-amyloid measurements. Alzheimer\u2019s Res Ther 2019;11:63. https:\/\/doi.org\/10.1186\/s13195-019-0517-9.","DOI":"10.1186\/s13195-019-0517-9"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_017","doi-asserted-by":"crossref","unstructured":"Mattsson, N, Andreasson, U, Persson, S, Arai, H, Batish, SD, Bernardini, S, et al.. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer\u2019s Dement 2011;7:386\u201395.e6. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2243.","DOI":"10.1016\/j.jalz.2011.05.2243"},{"key":"2023032404532957047_j_cclm-2022-0516_ref_018","unstructured":"Kuhlmann, J, Boulo, S, Andreasson, U, Bjerke, M, Pannee, J, Charoud-Got, J, et al.. CERTIFICATION REPORT: the certification of amyloid \u03b21-42 in CSF in ERM\u00ae-DA480\/IFCC, ERM\u00ae-DA481\/IFCC and ERM\u00ae-DA482\/IFCC, EUR 28691 EN. Luxembourg: Publications Office of the European Union; 2017. https:\/\/publications.jrc.ec.europa.eu\/repository\/handle\/JRC107381 [Accessed 7 July 2021]."},{"key":"2023032404532957047_j_cclm-2022-0516_ref_019","doi-asserted-by":"crossref","unstructured":"Palmqvist, S, Janelidze, S, Quiroz, YT, Zetterberg, H, Lopera, F, Stomrud, E, et al.. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020;324:772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","DOI":"10.1001\/jama.2020.12134"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0516\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0516\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:54:44Z","timestamp":1679619284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0516\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,8]]},"published-print":{"date-parts":[[2023,1,27]]}},"alternative-id":["10.1515\/cclm-2022-0516"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2022-0516","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]}}}